HIGHBuilt-in & outside partyProduct / Revenue mix
82%
MIPLYFFA
“10-K Item 1A: 'For the year ended December 31, 2025 we derived approximately 82% of our revenues from commercial sales of MIPLYFFA'”
ZVRA · Concentration risk · 10-K extracted
Zevra Therapeutics (ZVRA) concentration risks
Updated
The most significant concentration Zevra Therapeutics discloses is MIPLYFFA at 82%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Zevra Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Zevra Therapeutics' revenue is heavily concentrated in a single commercial product: approximately 82% of 2025 revenues were derived from commercial sales of MIPLYFFA, a high-share exposure with a mixed character, combining the structural fact of a single-product commercial base with the dependency-like sensitivity of that revenue to ongoing demand, pricing, and reimbursement dynamics for one drug. Because MIPLYFFA accounts for such a large share of the top line, any disruption to its commercial trajectory — whether from competitive entry, reimbursement changes, or manufacturing issues — would flow through to reported revenue with little offsetting diversification from other products. This single exposure is therefore the primary variable most capable of moving the verdict on Zevra, since there is no comparably sized second product disclosed here to cushion a shortfall. Investors evaluating Zevra should treat MIPLYFFA's continued commercial performance as effectively synonymous with the company's near-term revenue trajectory, recognizing that the 82% concentration is a feature of an early-stage commercial launch rather than a diversified, multi-product revenue base.
For the engine’s reasoning on ZVRA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ZVRA● | Zevra Therapeutics, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.